HRP20210872T1 - Liposomni adjuvantni pripravci - Google Patents
Liposomni adjuvantni pripravci Download PDFInfo
- Publication number
- HRP20210872T1 HRP20210872T1 HRP20210872TT HRP20210872T HRP20210872T1 HR P20210872 T1 HRP20210872 T1 HR P20210872T1 HR P20210872T T HRP20210872T T HR P20210872TT HR P20210872 T HRP20210872 T HR P20210872T HR P20210872 T1 HRP20210872 T1 HR P20210872T1
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine preparation
- antigens
- vaccine
- liposome
- alkyl
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims 5
- 239000000203 mixture Substances 0.000 title claims 4
- 238000002360 preparation method Methods 0.000 claims 21
- -1 l-α-aminobutyl Chemical group 0.000 claims 20
- 229960005486 vaccine Drugs 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 239000002502 liposome Substances 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000000890 antigenic effect Effects 0.000 claims 5
- 230000003308 immunostimulating effect Effects 0.000 claims 5
- 229930182490 saponin Natural products 0.000 claims 5
- 150000007949 saponins Chemical class 0.000 claims 5
- 235000017709 saponins Nutrition 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 3
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims 3
- 229930186217 Glycolipid Natural products 0.000 claims 3
- 229930182558 Sterol Natural products 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 3
- 150000003432 sterols Chemical class 0.000 claims 3
- 235000003702 sterols Nutrition 0.000 claims 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims 2
- 241000223924 Eimeria Species 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims 2
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 2
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims 2
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 241000725681 Swine influenza virus Species 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 244000144977 poultry Species 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 241000114864 ssRNA viruses Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 239000000232 Lipid Bilayer Substances 0.000 claims 1
- 102000011195 Profilin Human genes 0.000 claims 1
- 108050001408 Profilin Proteins 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 1
- 229940076810 beta sitosterol Drugs 0.000 claims 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229960002061 ergocalciferol Drugs 0.000 claims 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000003250 oocyst Anatomy 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 1
- 229950005143 sitosterol Drugs 0.000 claims 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims 1
- 235000016831 stigmasterol Nutrition 0.000 claims 1
- 229940032091 stigmasterol Drugs 0.000 claims 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 1
- 235000001892 vitamin D2 Nutrition 0.000 claims 1
- 239000011653 vitamin D2 Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Claims (23)
1. Liposom koji uglavnom ne sadrži saponine, naznačen time što sadrži vanjski lipid dvosloj membrana i unutarnji odjeljak, gdje vanjska membrana sadrži:
a) kvaternarni amonijev spoj, koji se sastoji od četiti alkilna lanca, od kojih su dva C10-C20 alkili, a preostala dva su C1-C4 alkili;
b) sterol kojeg se bira iz skupine koju čine β-sitosterol, stigmasterol, ergosterol, ergokalciferol, te kolesterol;
c) fosfolipid; i
d) glikolipid formule I:
[image]
,
gdje: R1 je vodik, ili zasićeni alkilni radikal s do 20 atoma ugljika; X je -CH2-, -O- ili -NH-; R2 je vodik, ili zasićeni ili nezasićeni alkilni radikal s do 20 atoma ugljika; R3, R4 i R5 su neovisno vodik, -SO42–, -PO42–, -COC1-10 alkil; R6 je l-alanil, l-α-aminobutil, l-arginil, l-asparginil, l-aspartil, l-cisteinil, l-glutamil, l-glicil, l-histidil, l-hidroksiprolil, l-izoleucil, l-leucil, l-lizil, l-metionil, l-ornitinil, l-fenilalanil, l-prolil, l-seril, l-treonil, l-tirozil, l-triptofanil, te l-valil ili njihovi d-izomeri.
2. Liposom u skladu s patentnim zahtjevom 1, naznačen time što navedeni liposom ne sadrži saponine.
3. Liposom u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je kvaternarni amonijev spoj DDA (dimetildioktadecilamonij), sterol je kolesterol, a glikolipid je N-(2-deoksi-2-l-leucilamino-β-d-glukopiranozil)-N-oktadecildodecanoilamid, ili njegova sol.
4. Liposom u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što dodatno sadrži, u unutarnjem odjeljku, imunostimulacijski oligonukleotid kojeg se bira iz skupine koju čine imunostimulacijski ribonukleotid, oligodeoksiribonukleotid CpG, te njihovu kombinaciju.
5. Liposom u skladu s patentnim zahtjevom 4, naznačen time što navedeni imunostimulacijski oligonukleotid sadrži bilo koji od SEQ ID NO 1-14.
6. Adjuvantna formulacija, naznačena time što sadrži liposom u skladu s bilo kojim od patentnih zahtjeva 1-5.
7. Adjuvant pripravak u skladu s patentnim zahtjevom 6, naznačen time što navedena adjuvantna formulacija uglavnom ne sadrži saponine.
8. Cjepivni pripravak, naznačen time što sadrži djelotvornu količinu antigene komponente i adjuvantne formulacije u skladu s patentnim zahtjevom 6 ili patentnim zahtjevom 7.
9. Cjepivni pripravak u skladu s patentnim zahtjevom 8, naznačen time što navedeni cjepivni pripravak uglavnom ne sadrži saponine.
10. Cjepivni pripravak u skladu s patentnim zahtjevom 8 ili 9, naznačen time što se antigena komponenta nalazi u unutarnjem odjeljku.
11. Cjepivni pripravak u skladu s bilo kojim od patentnih zahtjeva 8-10, naznačen time što antigena komponenta se bira iz skupine koju čine goveđi antigeni, kozji antigeni, svinjski antigeni, antigeni peradi, konjski antigeni, pseći antigeni, konjski antigeni i mačji antigeni.
12. Cjepivni pripravak u skladu s bilo kojim od patentnih zahtjeva 8-11, naznačen time što imunostimulacijski oligonukleotid sadrži oligodeoksiribonukleotid CpG.
13. Cjepivni pripravak u skladu s patentnim zahtjevom 9, naznačen time što antigena komponenta sadrži IBR, BVDV-1, te BVDV-2, te što cjepivni pripravak uglavnom ne sadrži saponine.
14. Cjepivni pripravak namijenjen upotrebi u postupku izazivanja imunosnog odgovora protiv virusa goveđe virusne dijareje (BVDV) kod goveda, naznačen time što se sastoji u primjeni na navedenom govedu cjepivnog pripravka u skladu s patentnim zahtjevom 13.
15. Cjepivni pripravak namijenjen upotrebi in postupak u skladu s patentnim zahtjevom 14, naznačen time što je navedeni imunosni odgovor izazvan bez popratne groznice.
16. Cjepivni pripravak u skladu s patentnim zahtjevom 12, naznačen time što antigen sadrži antigen peradi.
17. Cjepivni pripravak u skladu s patentnim zahtjevom 16, naznačen time što je antigen profilin.
18. Cjepivni pripravak namijenjen upotrebi u postupku sprječavanja rasipanja oocista parazita Eimeria kod životinje tipa peradi zaražene parazitom Eimeria, naznačen time što se sastoji u primjeni na navedenoj životinji cjepivnog pripravka u skladu s patentnim zahtjevom 17 prije navedene zaraze.
19. Cjepivni pripravak u skladu s patentnim zahtjevom 11, naznačen time što antigena komponenta sadrži ssRNA virus, te što cjepivni pripravak uglavnom ne sadrži oligodeoksiribonukleotid CpG.
20. Cjepivo u skladu s patentnim zahtjevom 19, naznačen time što je ssRNA virus virus influence.
21. Cjepivo u skladu s patentnim zahtjevom 20, naznačen time što je virus influence inaktivirani virus svinjske influence (SIV).
22. Postupak priprave liposoma u skladu s patentnim zahtjevom 1, naznačen time što se postupak sastoji u:
a) otapanju u organskom otapalu kvaternarnog amonijevog spoja, sterola, fosfolipida, te glikolipida formule I:
[image]
,
gdje: R1 je vodik, ili zasićeni alkilni radikal s do 20 atoma ugljika; X je -CH2-, -O- ili -NH-; R2 je vodik, ili zasićeni ili nezasićeni alkilni radikal s do 20 atoma ugljika; R3, R4 i R5 su neovisno vodik, -SO42–, -PO42–, -COC1-10 alkil; R6 je l-alanil, l-α-aminobutil, l-arginil, l-asparginil, l-aspartil, l-cisteinil, l-glutamil, l-glicil, l-histidil, l-hidroksiprolil, l-izoleucil, l-leucil, l-lizil, l-metionil, l-ornitinil, l-fenilalanil, l-prolil, l-seril, l-treonil, l-tirozil, l-triptofanil, te l-valil ili njihovi d-izomeri;
b) uklanjanju organskog otapala i stvaranje filma;
c) rehidriranju filma u vodenom otapalu, čime se dobije rehidrirani pripravak;
d) mikrofluidiziranju rehidriranog pripravka.
23. Postupak u skladu s patentnim zahtjevom 22, naznačen time što vodeno otapalo sadrži imunostimulacijski oligonukleotid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194355P | 2015-07-20 | 2015-07-20 | |
| PCT/US2016/042882 WO2017015252A1 (en) | 2015-07-20 | 2016-07-19 | Liposomal adjuvant compositions |
| EP16745318.2A EP3325015B1 (en) | 2015-07-20 | 2016-07-19 | Liposomal adjuvant compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210872T1 true HRP20210872T1 (hr) | 2021-07-09 |
Family
ID=56555804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210872TT HRP20210872T1 (hr) | 2015-07-20 | 2021-06-01 | Liposomni adjuvantni pripravci |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP3325015B1 (hr) |
| JP (1) | JP6975132B2 (hr) |
| KR (1) | KR102085968B1 (hr) |
| CN (1) | CN107847603B (hr) |
| AR (1) | AR105393A1 (hr) |
| AU (1) | AU2016297529B2 (hr) |
| BR (1) | BR112018001318B1 (hr) |
| CA (1) | CA2992892C (hr) |
| CL (1) | CL2018000155A1 (hr) |
| CO (1) | CO2018000496A2 (hr) |
| CY (1) | CY1124319T1 (hr) |
| DK (1) | DK3325015T3 (hr) |
| ES (1) | ES2878475T3 (hr) |
| HK (1) | HK1250338A1 (hr) |
| HR (1) | HRP20210872T1 (hr) |
| HU (1) | HUE054422T2 (hr) |
| LT (1) | LT3325015T (hr) |
| MX (1) | MX2018000879A (hr) |
| PH (1) | PH12018500146A1 (hr) |
| PL (1) | PL3325015T3 (hr) |
| PT (1) | PT3325015T (hr) |
| RS (1) | RS62015B1 (hr) |
| RU (1) | RU2736642C2 (hr) |
| SI (1) | SI3325015T1 (hr) |
| TW (1) | TWI655002B (hr) |
| UA (1) | UA125017C2 (hr) |
| WO (1) | WO2017015252A1 (hr) |
| ZA (1) | ZA201800285B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206098A (zh) * | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3521994A1 (de) * | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
| WO1998048836A1 (fr) * | 1997-04-30 | 1998-11-05 | Merieux Oravax | Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1 |
| US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
| US7749520B2 (en) * | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| CN1980638B (zh) * | 2004-07-07 | 2011-10-12 | 国立血清研究所 | 用糖脂稳定基于脂质的佐剂制剂的组合物和方法 |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| ME01545B (me) * | 2006-01-26 | 2014-04-20 | Zoetis Services Llc | Preparati s novim glikolipidnim adjuvansom |
| ES2728949T3 (es) * | 2008-06-27 | 2019-10-29 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| BRPI1014494A2 (pt) * | 2009-04-30 | 2016-08-02 | Coley Pharm Group Inc | vacina pneumocócica e usos da mesma |
| NZ620441A (en) * | 2009-09-03 | 2015-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| CN103025351B (zh) * | 2010-05-28 | 2016-08-24 | 佐蒂斯比利时股份有限公司 | 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗 |
| CN103619325A (zh) * | 2011-07-04 | 2014-03-05 | 国立血清研究所 | 用于生产脂质体的方法 |
| CN102973506B (zh) * | 2011-09-05 | 2015-06-03 | 中国科学院深圳先进技术研究院 | 阳离子脂质体及其制备方法 |
| ES2894138T3 (es) * | 2013-05-14 | 2022-02-11 | Zoetis Services Llc | Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes |
| AU2014321369B2 (en) * | 2013-09-19 | 2020-04-16 | Zoetis Services Llc | Oil-based adjuvants |
| FR3012964A1 (fr) * | 2013-11-12 | 2015-05-15 | Seppic Sa | Vaccins adjuves pour vaccination aviaire in ovo |
-
2016
- 2016-07-19 RS RS20210785A patent/RS62015B1/sr unknown
- 2016-07-19 KR KR1020187004751A patent/KR102085968B1/ko active IP Right Grant
- 2016-07-19 JP JP2018502803A patent/JP6975132B2/ja active Active
- 2016-07-19 EP EP16745318.2A patent/EP3325015B1/en active Active
- 2016-07-19 PT PT167453182T patent/PT3325015T/pt unknown
- 2016-07-19 HU HUE16745318A patent/HUE054422T2/hu unknown
- 2016-07-19 RU RU2018102114A patent/RU2736642C2/ru active
- 2016-07-19 CN CN201680042420.3A patent/CN107847603B/zh active Active
- 2016-07-19 SI SI201631259T patent/SI3325015T1/sl unknown
- 2016-07-19 AR ARP160102185A patent/AR105393A1/es unknown
- 2016-07-19 DK DK16745318.2T patent/DK3325015T3/da active
- 2016-07-19 PL PL16745318T patent/PL3325015T3/pl unknown
- 2016-07-19 BR BR112018001318-8A patent/BR112018001318B1/pt active IP Right Grant
- 2016-07-19 UA UAA201800567A patent/UA125017C2/uk unknown
- 2016-07-19 TW TW105122775A patent/TWI655002B/zh active
- 2016-07-19 LT LTEP16745318.2T patent/LT3325015T/lt unknown
- 2016-07-19 MX MX2018000879A patent/MX2018000879A/es unknown
- 2016-07-19 ES ES16745318T patent/ES2878475T3/es active Active
- 2016-07-19 CA CA2992892A patent/CA2992892C/en active Active
- 2016-07-19 WO PCT/US2016/042882 patent/WO2017015252A1/en active Application Filing
- 2016-07-19 AU AU2016297529A patent/AU2016297529B2/en active Active
-
2018
- 2018-01-16 ZA ZA2018/00285A patent/ZA201800285B/en unknown
- 2018-01-18 PH PH12018500146A patent/PH12018500146A1/en unknown
- 2018-01-19 CL CL2018000155A patent/CL2018000155A1/es unknown
- 2018-01-19 CO CONC2018/0000496A patent/CO2018000496A2/es unknown
- 2018-07-27 HK HK18109762.7A patent/HK1250338A1/zh unknown
-
2021
- 2021-06-01 HR HRP20210872TT patent/HRP20210872T1/hr unknown
- 2021-07-14 CY CY20211100637T patent/CY1124319T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016109925A (ru) | Адъюванты на масляной основе | |
| JP2022121437A5 (hr) | ||
| AU646257B2 (en) | Oral vaccine comprising antigen surface-associated with red blood cells | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| TWI301067B (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
| HRP20141122T1 (hr) | Cjepivo protiv influence | |
| HRP20130939T1 (hr) | Emulzijski cjepivni pripravci koji sadrže antigen i adjuvans u vodenoj fazi | |
| BR112013018074A2 (pt) | métodos para a preparação de vesículas e formulações produzidas a partir dessas | |
| AR059192A1 (es) | Composiciones coadyuvantes glicolipidicas | |
| HRP20210872T1 (hr) | Liposomni adjuvantni pripravci | |
| ES2227698T3 (es) | Formulacion de lipidos inmunoestimuladores. | |
| ES2807607T3 (es) | Métodos para proporcionar virosomas con adyuvante y virosomas con adyuvante obtenibles de esta manera | |
| US20230100089A1 (en) | Methods and composition for induction of immune response | |
| WO2012042003A1 (en) | Improved vaccine compositions | |
| US20230225972A1 (en) | Liposomal composition for preventing or early treatment of pathogenic infection | |
| RU2020113283A (ru) | Адъюванты на масляной основе | |
| AR123110A1 (es) | Vacunas anticoronavirus |